Key Segmentation
By Indication
- Plaque Psoriasis
- Inflammatory Bowel Disease
- Psoriatic Arthritis
- Others
By Route of Administration
- Subcutaneous
- Intravenous
By Distribution Channel
- Specialty Pharmacies
- Hospital Pharmacies
- Others
By End User
- Dermatology Clinics
- Gastroenterology Clinics
- Others
Regional Coverage:
North America
- US
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- ASEAN Countries
- Rest of Asia Pacific
Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of Middle East & Africa
Latin America
- Brazil
- Argentina
- Mexico
- Colombia
- Rest of Latin America
Available Customization
With the given market data SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
- Detailed Volume Analysis
- Criss-Cross segment analysis (e.g. Product X Application)
- Competitive Product Benchmarking
- Geographic Analysis
- Additional countries in any of the regions
- Customized Data Representation
- Detailed analysis and profiling of additional market players
Frequently Asked Questions
The Tremfya Market is expected to grow at a CAGR of 7.98% from 2026 to 2035.
The Tremfya Market was valued at USD 3.88 Billion in 2025.
Expanding therapeutic indications into inflammatory bowel disease combined with clinical differentiation in structural joint damage inhibition is the major growth factor.
The Plaque Psoriasis segment held approximately 87.30% share in 2025.
North America held the largest share of the Tremfya Market in 2025, at over 85.00%, while Asia Pacific was the fastest-growing region.
Get in Touch
